Document is current
Any future updates will be listed below
-
Authors
Mei, Xueyan https://orcid.org/0000-0001-7224-7318
Lee, Hao-Chih
Diao, Kai-yue
Huang, Mingqian
Lin, Bin https://orcid.org/0000-0002-3647-2144
Liu, Chenyu https://orcid.org/0000-0002-1935-7179
Xie, Zongyu
Ma, Yixuan
Robson, Philip M.
Chung, Michael https://orcid.org/0000-0002-0976-4088
Bernheim, Adam
Mani, Venkatesh
Calcagno, Claudia
Li, Kunwei
Li, Shaolin
Shan, Hong
Lv, Jian
Zhao, Tongtong
Xia, Junli
Long, Qihua
Steinberger, Sharon
Jacobi, Adam
Deyer, Timothy https://orcid.org/0000-0001-5606-7106
Luksza, Marta
Liu, Fang https://orcid.org/0000-0001-8032-6681
Little, Brent P.
Fayad, Zahi A. https://orcid.org/0000-0002-3439-7347
Yang, Yang https://orcid.org/0000-0002-2841-4243
-
Funding
Funding for this research was provided by:
from Astra Zeneca, Daiichi Sankyo, Alexion and Horizon Pharma
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001433)
- License Information
-
More Information
Article History
Received: 14 February 2020
Accepted: 7 May 2020
First Online: 19 May 2020
Competing interests
: Z.A.F. discloses consulting fees from Alexion and GlaxoSmithKline and research funding from Daiichi Sankyo; Amgen; Bristol Myers Squibb; and Siemens Healthineers. Z.A.F. receives financial compensation as a board member and advisor to Trained Therapeutix Discovery and owns equity in Trained Therapeutix Discovery as co-founder. A.B. is on the medical advisory board of RADLogics. B.P.L. is an academic textbook author and associate editor for Elsevier, Inc., and receives royalties for his work. Other authors have no other competing interests to disclose.
Free to read: This content has been made available to all.
